- Allakos Inc To discuss Lirentelimab Phase 2 Results TranscriptJan 16, 2024
- Allakos Inc Investor Day TranscriptFeb 15, 2022
- Allakos Inc Results From Phase 1 Study Of Subcutaneously Administered Lirentelimab (AK002) Call TranscriptOct 26, 2020
- Allakos Inc. - Special Call TranscriptMar 24, 2020
- Allakos Inc. - Special Call TranscriptAug 05, 2019
- Allakos Inc Annual Shareholders Meeting TranscriptJun 06, 2019
- Allakos Inc. - Special Call TranscriptMay 07, 2019
Allakos Inc Investor Day Transcript
Greetings, and welcome to the Allakos Investor Day. (Operator Instructions) As a reminder, this conference is being recorded. I'll now turn the conference over to Mr. Robert Alexander, CEO.
Mr. Alexander, you may now begin your presentation.
All right. Thank you. Good morning, everyone, and thank you for joining the call.
Before we begin, a reminder that we will be making forward-looking statements, so please refer to our filings with the SEC. With me here today are Craig Paterson, our Chief Medical Officer; Baird Radford, our CFO; Brad Youngblood, our Head of Research; and Adam Tomasi, our President and COO.
As for the agenda, we -- following my introductory remarks, Craig will go through our KRYPTOS and ENIGMA studies. We'll then be joined by Dr. Evan Dellon, to give his perspective on the EGID space and specifically these 2 clinical studies. I will then go through the scientific rationale for our programs with lirentelimab and atopic derm and chronic spontaneous urticaria.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)